There are 2789 resources available
279P - Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
Presenter: Cristina Saura Manich
Session: ePoster Display
280P - Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial
Presenter: Rupert Bartsch
Session: ePoster Display
281P - Prognostic impact of immune interactions in HER2+ and triple-negative breast cancer brain metastases
Presenter: Gaia Griguolo
Session: ePoster Display
370P - Prospective study of apatinib combined with whole brain radiation therapy and simultaneous integrated boost for brain metastases from lung cancer
Presenter: Guang Han
Session: ePoster Display
283P - Treatment landscape of HER2-positive metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry
Presenter: Simon Peter Gampenrieder
Session: ePoster Display
372P - The prognostic value of liver metastases and how affects the applicability of the lung-molGPA in non-small cell lung cancer patients with brain metastases
Presenter: Joel Rafael Veas Rodriguez
Session: ePoster Display
285P - Real-world outcomes associated with pyrotinib-based therapy for HER2-positive metastatic breast cancer
Presenter: Li Hao
Session: ePoster Display
286P - Outcome of patients with HER2-positive brain metastatic breast cancer: A 10-year retrospective study
Presenter: Cecile Bigot
Session: ePoster Display
305P - Real-world health-related quality of life (HRQoL) among HER2-negative (HER2-) advanced breast cancer (ABC) patients in EU3 and US
Presenter: Katie Lewis
Session: ePoster Display
288P - Real-world outcomes and safety of pyrotinib in HER2-positive metastatic breast cancer (MBC) patients: A prospective cohort study
Presenter: Ting Luo
Session: ePoster Display